Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
All articles by Waseem Qureshi
Dose-Intensive Chemoimmunotherapy “Preferred” for Untreated PMBCL
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Eliminating H2RAs From Paclitaxel Premedication Does Not Increase Infusion Reactions
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Atezolizumab Yields Durable Responses in Alveolar Soft Part Sarcoma
Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.
Nimotuzumab Improves OS, PFS in KRAS Wild-Type Advanced Pancreatic Cancer
Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
Screening Confers “Small” Survival Benefit in High-Grade Serous Ovarian Cancer
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
Language Barriers Hinder Access to Cancer Care Even Before Patients See a Doctor
Language barriers may hinder access to cancer care before patients even encounter a physician, a new study suggests.
Cancer Patients Have Higher Prevalence of Myocardial Infarction as Cause of Chest Pain
Patients with current or past cancer have a higher prevalence of acute myocardial infarction as the cause of chest pain than patients without cancer.
High Prevalence of BRCA2 Variants in Pancreatic Acinar Cell Carcinoma
In a pan-cancer analysis, patients with pancreatic acinar cell carcinoma had the highest prevalence of BRCA2 germline pathogenic variants.
Tumor-Treating Fields Therapy Improves Survival in Metastatic NSCLC
Adding tumor-treating fields therapy to standard treatment improves survival in patients with metastatic non-small cell lung cancer, a study suggests.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...